Your browser doesn't support javascript.
loading
PET imaging of putative microglial activation in individuals at ultra-high risk for psychosis, recently diagnosed and chronically ill with schizophrenia.
Di Biase, M A; Zalesky, A; O'keefe, G; Laskaris, L; Baune, B T; Weickert, C S; Olver, J; McGorry, P D; Amminger, G P; Nelson, B; Scott, A M; Hickie, I; Banati, R; Turkheimer, F; Yaqub, M; Everall, I P; Pantelis, C; Cropley, V.
Afiliação
  • Di Biase MA; Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne and Melbourne Health, Carlton South, VIC, Australia.
  • Zalesky A; Department of Psychiatry, The University of Melbourne, Parkville, VIC Australia.
  • O'keefe G; Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne and Melbourne Health, Carlton South, VIC, Australia.
  • Laskaris L; Department of Psychiatry, The University of Melbourne, Parkville, VIC Australia.
  • Baune BT; Melbourne School of Engineering, The University of Melbourne, Parkville, VIC Australia.
  • Weickert CS; Department of Molecular Imaging and Therapy, The University of Melbourne, Heidelberg, VIC Australia.
  • Olver J; Department of Medicine, The University of Melbourne, and La Trobe University, Austin Hospital, Heidelberg, VIC, Australia.
  • McGorry PD; Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne and Melbourne Health, Carlton South, VIC, Australia.
  • Amminger GP; Department of Psychiatry, The University of Melbourne, Parkville, VIC Australia.
  • Nelson B; Discipline of Psychiatry, The University of Adelaide, Adelaide, SA, Australia.
  • Scott AM; Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne and Melbourne Health, Carlton South, VIC, Australia.
  • Hickie I; Neuroscience Research Australia, Randwick, NSW, Australia.
  • Banati R; Schizophrenia Research Institute, Randwick, NSW, Australia.
  • Turkheimer F; School of Psychiatry, University of New South Wales, Sydney, NSW, Australia.
  • Yaqub M; Department of Psychiatry, The University of Melbourne, Parkville, VIC Australia.
  • Everall IP; Department of Molecular Imaging and Therapy, The University of Melbourne, Heidelberg, VIC Australia.
  • Pantelis C; Department of Medicine, The University of Melbourne, and La Trobe University, Austin Hospital, Heidelberg, VIC, Australia.
  • Cropley V; Orygen, The National Centre of Excellence in Youth Mental Health, Parkville, VIC, Australia.
Transl Psychiatry ; 7(8): e1225, 2017 08 29.
Article em En | MEDLINE | ID: mdl-28850113
ABSTRACT
We examined putative microglial activation as a function of illness course in schizophrenia. Microglial activity was quantified using [11C](R)-(1-[2-chrorophynyl]-N-methyl-N-[1-methylpropyl]-3 isoquinoline carboxamide (11C-(R)-PK11195) positron emission tomography (PET) in (i) 10 individuals at ultra-high risk (UHR) of psychosis; (ii) 18 patients recently diagnosed with schizophrenia; (iii) 15 patients chronically ill with schizophrenia; and, (iv) 27 age-matched healthy controls. Regional-binding potential (BPND) was calculated using the simplified reference-tissue model with four alternative reference inputs. The UHR, recent-onset and chronic patient groups were compared to age-matched healthy control groups to examine between-group BPND differences in 6 regions dorsal frontal, orbital frontal, anterior cingulate, medial temporal, thalamus and insula. Correlation analysis tested for BPND associations with gray matter volume, peripheral cytokines and clinical variables. The null hypothesis of equality in BPND between patients (UHR, recent-onset and chronic) and respective healthy control groups (younger and older) was not rejected for any group comparison or region. Across all subjects, BPND was positively correlated to age in the thalamus (r=0.43, P=0.008, false discovery rate). No correlations with regional gray matter, peripheral cytokine levels or clinical symptoms were detected. We therefore found no evidence of microglial activation in groups of individuals at high risk, recently diagnosed or chronically ill with schizophrenia. While the possibility of 11C-(R)-PK11195-binding differences in certain patient subgroups remains, the patient cohorts in our study, who also displayed normal peripheral cytokine profiles, do not substantiate the assumption of microglial activation in schizophrenia as a regular and defining feature, as measured by 11C-(R)-PK11195 BPND.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transtornos Psicóticos / Esquizofrenia / Encéfalo / Receptores de GABA / Microglia Tipo de estudo: Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Female / Humans / Male Idioma: En Revista: Transl Psychiatry Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Austrália

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transtornos Psicóticos / Esquizofrenia / Encéfalo / Receptores de GABA / Microglia Tipo de estudo: Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Female / Humans / Male Idioma: En Revista: Transl Psychiatry Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Austrália